KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Long-Term Investments: 2009-2024

Historic Long-Term Investments for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Dec 2024 value amounting to $68.6 million.

  • Alnylam Pharmaceuticals' Long-Term Investments fell 25.19% to $51.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.3 million, marking a year-over-year decrease of 25.19%. This contributed to the annual value of $68.6 million for FY2024, which is 38.88% up from last year.
  • As of FY2024, Alnylam Pharmaceuticals' Long-Term Investments stood at $68.6 million, which was up 38.88% from $49.4 million recorded in FY2023.
  • In the past 5 years, Alnylam Pharmaceuticals' Long-Term Investments registered a high of $68.6 million during FY2024, and its lowest value of $40.7 million during FY2020.
  • Its 3-year average for Long-Term Investments is $55.8 million, with a median of $49.4 million in 2023.
  • Data for Alnylam Pharmaceuticals' Long-Term Investments shows a peak YoY soared of 174.70% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Alnylam Pharmaceuticals' Long-Term Investments stood at $40.7 million in 2020, then increased by 0.41% to $40.9 million in 2021, then increased by 20.78% to $49.4 million in 2022, then rose by 0.00% to $49.4 million in 2023, then surged by 38.88% to $68.6 million in 2024.